H
HiFiBiO Therapeutics
An emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, Massachusetts. The company is committed to improving patient lives with single-cell precision. This means they focus on developing treatments that target individual cells, which can be more effective and have fewer side effects than traditional treatments.
Read full description
HiFiBiO Therapeutics operates in the biotech market, serving clients in the healthcare sector, including hospitals, clinics, and other medical facilities. Their business model revolves around the development and commercialization of innovative biotech solutions, particularly in the field of drug discovery and development.
One of their key innovations is the Drug Intelligence Science (DIS®) platform, a proprietary translational platform that uses artificial intelligence (AI) to enhance the success rate of drug discovery and development. This platform was recognized as the "AI Innovation of the Year" in the 2023 BioTech Breakthrough Awards, highlighting its potential to revolutionize the biotech industry.
Furthermore, HiFiBiO Therapeutics has received approval from the Chinese National Medical Products Administration (NMPA) for their Investigational New Drug (IND) application for HFB200301, an innovative anti-tumor monoclonal antibody. This is a type of drug that can recognize and attack specific cells in the body, in this case, tumor cells.
The company generates revenue through the development and sale of these innovative biotech solutions, as well as through partnerships with other healthcare and biotech companies.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, DNA, Microfluidics, Genetics and genomics, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health
- Business model
- Manufacturing
- Investment activity
- 1 company, latest Oct 2018
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2021 | $75M | $300M | IDG Capital · B Capital · Hong Kong Science & Technology Parks Corporation · Legend Star | — |
| SERIES COther financing | Aug 2019 | $67M | $268M | IDG Capital · Sequoia | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for HiFiBiO Therapeutics is 2.5K monthly website visits, down 30.6% over the last three months. HiFiBiO Therapeutics's team declined 27.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Nest.Bio Labs
Virtus Inspire Ventures
Sequoia
LYFE Capital- LSLegend Star
Proxima Ventures
Series B and later9 investors entered at this stage
IDG Capital
B Capital
Hong Kong Science & Technology Parks Corporation- MCMaison Capital
Grand Mount Capital
Trinity Innovation Fund
Hengxu Capital
Mirae Asset Capital
Sherpa Venture Partners
Other known investors4 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
SATT Conectus
University of Strasbourg
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HiFiBiO Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HiFiBiO Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.